Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma.

Trial Profile

Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Thiotepa (Primary) ; Antineoplastics
  • Indications Osteosarcoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms OSII-TTP
  • Most Recent Events

    • 01 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Aug 2013 Planned end date changed from 1 Sep 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.
    • 17 Dec 2012 Planned End Date changed from 1 Jul 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top